Alexza reports migraine data

Alexza (NASDAQ:ALXA) said two of three doses of Staccato loxapine ( AZ-104) met the primary endpoint of superiority vs. placebo for two-hour pain relief in the Phase IIa AMDC 104-201 trial to treat mi...